Immunogene therapy with IL-12- and IL-15-engineered neuroblastoma Neuro2a cells showed therapeutic efficacy by enhancement of CD8+ T-cell immunoresponses and potentiated the survivability of neuroblastoma-bearing syngenic mice [98]. The gene discussed is IL15; the disease is neuroblastoma.